(Q44025718)

29 November 2017

title

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. (English)

1 reference

29 November 2017

main subject

hepatocellular carcinoma

1 reference

Jeong Eun Kim

1

1 reference

29 November 2017

Baek-Yeol Ryoo

2

1 reference

29 November 2017

Min-Hee Ryu

3

1 reference

29 November 2017

Heung-Moon Chang

4

1 reference

29 November 2017

Dong Jin Suh

5

1 reference

29 November 2017

Han Chu Lee

6

1 reference

29 November 2017

Young-Suk Lim

7

1 reference

29 November 2017

Kang Mo Kim

8

1 reference

29 November 2017

Yoon-Koo Kang

9

1 reference

29 November 2017

publication date

29 March 2011

1 reference

Cancer Chemotherapy and Pharmacology

29 November 2017

published in

1 reference

29 November 2017

volume

68

1 reference

29 November 2017

issue

5

1 reference

29 November 2017

page(s)

1285-1290

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1616-x

29 November 2017

exact match

0 references

cites work

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1616-X

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1616-X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1616-X

Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1616-X

10.1007/S00280-011-1616-X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference